776-P: Glycemic Outcomes after Six Months of Real-World MiniMed 780G Advanced Hybrid Closed-Loop (AHCL) Therapy Use in Chile

Abstract

Objective: MiniMed™ 780G system use has improved glycemic control in clinical trials1,2 and real-world data analyses3. This study evaluated real-word glycemic outcomes before and 6 months after AHCL initiation by individuals with T1D living in Chile. Methods: Data from 37 MiniMed™ 780G users (aged 5-76 years, mean±SD of 29.3±19.3 years) at 12 centers throughout Chile were prospectively collected and analyzed. Mean glucose management indicator (GMI) , sensor and system use, and time spent at SG ranges including target SG range (TIR, 70-180mg/dL) were determined using 14 days of SG data at baseline and 2, 14, 28, 90 and 180 days post-AHCL initiation. Results: Overall, ≥95% of time was spent in AHCL (Figure 1) and GMI was <7% throughout the study. TIR increased from 68.9% to 79.5% in 7 former MiniMed™ 640G users and from 75.3% to 78.1% in 30 former MiniMed™ 670G users. The percentage of users achieving TIR >70% and GMI <7.0% increased from 63.6% to 86.5% and from 70.3% to 82.4% by 180 days post-AHCL initiation, respectively. Conclusion: MiniMed™ 780G use in Chile allowed most to increase TIR within 2 weeks, an important outcome that was sustained over 6 months. Disclosure M.Castro: Employee; Medtronic. C.Carrasco bonilla: Employee; Medtronic. J.C.Leon macedo: Employee; Medtronic. M.Gutierrez: Employee; Medtronic. Z.C.Valera lopez: Employee; Medtronic. A.Daghero: Employee; Medtronic.